Corrigendum to ‘Impact of Bridge-to-Bridge Strategies from Paracorporeal to Implantable Left Ventricular Assist Devices on the Pre-Heart Transplant Outcome: A single-center analysis of 134 cases’ [Journal of Cardiology 77 (2021) 408–416] (Journal of Cardiology (2021) 77(4) (408–416), (S0914508720303634), (10.1016/j.jjcc.2020.11.003))

While reviewing the original publication of this article, errors have been identified in the sentences, tables and figures. We regret these errors. In Tables 1–4, there were several errors in the values. The corrected Tables are as follows. Corrected values were written in bold. In Fig. 3(B), the P value was corrected. It should read “0.031″, not “0.030″ as given previously. In Fig. 4, the values in the categories of ‘Primary iLVAD T-bil < 1.3′ and ‘BTB T-bil ≥ 1.3′ were corrected. They should read “43.7″ and “77.8″, not “43.6″ and “77.7″ as given previously. The corresponding numerical values in the sentences have also been corrected. Corrected values were written in bold. 1. Page 408, line 9–14 in the Abstract The following sentences are not correct: However, the 1-year survival rate and the 1-year freedom from the composite events of death, stroke, systemic infection, and bleeding rate were lower in the BTB group than in the primary iLVAD group (survival rate, 88.2% vs. 99.0%, p = 0.0040; composite event-free survival rate, 26.1% vs. 49.8%, p = 0.030; log-rank test). Multivariate analysis indicated that the BTB strategy [hazard ratio (HR) 1.70, 95% confidence intervals (CI) 1.03–2.72; p = 0.036] and serum total bilirubin levels at iLVAD implantation [HR 1.31, 95% CI 1.00–1.65; p = 0.043] were independent predictors of 1-year composite events. The correct sentences are as follows: However, the 1-year survival rate and the 1-year freedom from the composite events of death, stroke, systemic infection, and bleeding rate were lower in the BTB group than in the primary iLVAD group (survival rate, 88.2% vs. 99.0%, p = 0.0040; composite event-free survival rate, 26.1% vs. 49.8%, p = 0.031; log-rank test). Multivariate analysis indicated that the BTB strategy [hazard ratio (HR) 1.70, 95% confidence intervals (CI) 1.03–2.73; p = 0.037] and serum total bilirubin levels at iLVAD implantation [HR 1.32, 95% CI 1.01–1.65; p = 0.043] were independent predictors of 1-year composite events. 2.Page 412, line 28–46 in the Result, Survival rate and iLVAD-related adverse events The following sentences are not correct: Similarly, the 1-year composite event-free survival rate was lower in the BTB group (26.1% vs. 49.8%, p = 0.030; log-rank test) (Fig. 3B). We investigated the pre-iLVAD operative predictors of 1-year composite events. In the univariate analysis, the BTB strategy (HR 1.68, 95% CI 1.02–2.70; p = 0.039) and serum T-bil levels at iLVAD implantation (HR 1.30, 95% CI 1.00–1.62; p = 0.046) were significant predictors of 1-year composite events. Similarly, in the multivariate analysis, the independent predictors of 1-year composite events were the BTB strategy (HR 1.70, 95% CI 1.03–2.72; p = 0.036) and serum T-bil levels at iLVAD implantation (HR 1.31, 95% CI 1.00–1.65; p = 0.043) (Table 4). The percentage of patients with the composite events was investigated in subgroups stratified according to the use of BTB strategy and the T-bil level. When we divided the 134 patients into four groups [BTB group with T-bil < 1.3 mg/dL (n = 25), BTB group with T-bil ≥ 1.3 mg/dL (n = 9), primary-iLVAD group with T-bil < 1.3 mg/dL (n = 71), primary-iLVAD group with T-bil ≥ 1.3 mg/dl (n = 29)], it was highest at 77.7% in BTB patients with high preoperative T-bil levels (Fig. 4). The correct sentences are as follows: Similarly, the 1-year composite event-free survival rate was lower in the BTB group (26.1% vs. 49.8%, p = 0.031; log-rank test) (Fig. 3B). We investigated the pre-iLVAD operative predictors of 1-year composite events. In the univariate analysis, the BTB strategy (HR 1.69, 95% CI 1.03–2.70; p = 0.040) and serum T-bil levels at iLVAD implantation (HR 1.30, 95% CI 1.00–1.63; p = 0.046) were significant predictors of 1-year composite events. Similarly, in the multivariate analysis, the independent predictors of 1-year composite events were the BTB strategy (HR 1.70, 95% CI 1.03–2.73; p = 0.037) and serum T-bil levels at iLVAD implantation (HR 1.32, 95% CI 1.01–1.65; p = 0.043) (Table 4). The percentage of patients with the composite events was investigated in subgroups stratified according to the use of BTB strategy and the T-bil level. When we divided the 134 patients into four groups [BTB group with T-bil < 1.3 mg/dL (n = 25), BTB group with T-bil ≥ 1.3 mg/dL (n = 9), primary-iLVAD group with T-bil <1.3 mg/dL (n = 71), primary-iLVAD group with T-bil ≥ 1.3 mg/dl (n = 29)], it was highest at 77.8% in BTB patients with high preoperative T-bil levels (Fig. 4). The authors would like to apologise for any inconvenience caused.